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There	is	no	treatment	for	the	neurodegenerative	disorder	Huntington	disease	(HD).	Cystamine	is	a	candidate	
drug;	however,	the	mechanisms	by	which	it	operates	remain	unclear.	We	show	here	that	cystamine	increases	lev-
els	of	the	heat	shock	DnaJ-containing	protein	1b	(HSJ1b)	that	are	low	in	HD	patients.	HSJ1b	inhibits	polyQ-hun-
tingtin–induced	death	of	striatal	neurons	and	neuronal	dysfunction	in	Caenorhabditis elegans.	This	neuroprotec-
tive	effect	involves	stimulation	of	the	secretory	pathway	through	formation	of	clathrin-coated	vesicles	containing	
brain-derived	neurotrophic	factor	(BDNF).	Cystamine	increases	BDNF	secretion	from	the	Golgi	region	that	is	
blocked	by	reducing	HSJ1b	levels	or	by	overexpressing	transglutaminase.	We	demonstrate	that	cysteamine,	the	
FDA-approved	reduced	form	of	cystamine,	is	neuroprotective	in	HD	mice	by	increasing	BDNF	levels	in	brain.	
Finally,	cysteamine	increases	serum	levels	of	BDNF	in	mouse	and	primate	models	of	HD.	Therefore,	cysteamine	
is	a	potential	treatment	for	HD,	and	serum	BDNF	levels	can	be	used	as	a	biomarker	for	drug	efficacy.
Introduction
Huntington disease (HD) is a devastating neurodegenerative dis-
order characterized by involuntary abnormal movements, person-
ality changes, and dementia (1). The dominantly inherited causal 
gene encodes the huntingtin protein, which contains an abnormal 
polyglutamine (polyQ) expansion in HD patients. HD develops 
when the expansion exceeds 35 glutamine residues, and there is 
a strong inverse correlation between the number of residues and 
the age at onset. HD is characterized by the preferential dysfunc-
tion and death of striatal neurons in the brain and the presence of 
neuritic and intranuclear inclusions in neurons (2).
There is currently no effective treatment to prevent or delay 
disease progression, and death usually occurs within 10–20 
years after the appearance of the first clinical symptoms. One 
of the most promising candidate drugs for HD is cystamine, a 
compound described as an in vitro transglutaminase (TGase) 
inhibitor. TGase is a calcium-dependent enzyme that catalyzes 
the formation of ε−(γ-glutamyl)lysine isopeptide bonds between 
a polypeptide-bound glutamine and a lysine of the protein sub-
strate (3, 4). TGase is suspected of participating in HD patho-
genesis (5). PolyQ-containing peptides and polyQ-huntingtin are 
substrates for TGase (6, 7). Moreover, TGase is upregulated in the 
brains of HD patients and of HD mice (8–11).
Given their enzymatic properties, TGases might promote aggre-
gate formation in HD. The observations that TGase is recruited 
into neuronal intranuclear inclusions (NIIs) (10, 12) and that NIIs 
are reduced in a cystamine-treated mouse model of HD (10) are 
consistent with this idea. However, cystamine treatment of HD 
mice does not necessarily result in fewer NIIs (11), and an increase 
in NIIs is observed in HD mice that are deficient for 1 of the TGase 
isoenzymes, tissue TGase 2 (TGase 2) (13, 14). Nevertheless, both 
HD mice lacking TGase 2 and HD mice treated with cystamine 
have less neuronal death, improved motor performance, and pro-
longed survival (10, 11, 13–15). In addition to its role as an in vitro 
inhibitor of TGase, cystamine could act through other mecha-
nisms (14, 16, 17). It inhibits caspase 3 activity and increases the 
levels of glutathione in cell models (18). It also increases the level 
of l-cysteine in cell models and animals (17, 19).
To understand better the beneficial effects of cystamine, Kar-
puj and colleagues treated HD mice with cystamine and analyzed 
large-scale profiles of transcription in the brain, where they identi-
fied genes whose transcription was specifically influenced by cys-
tamine treatment (11). In particular, transcripts of DnaJ-type heat 
shock proteins (Hsps) were elevated upon cystamine treatment 
(11). Numerous other studies have highlighted the important role 
of Hsps in HD and in other polyQ disorders in cellular and animal 
models (for reviews, see refs. 20–22). Hsps are of particular relevance 
to HD not only because they prevent aggregation of mutant proteins 
and solubilize aggregated proteins but also because they promote 
ubiquitination and degradation of abnormal proteins and suppress 
the antiapoptotic program (22, 23). Cystamine might, therefore, be 
protective in HD by increasing the transcription of Hsps that, in 
turn, protect cells against polyQ-huntingtin–induced toxicity.
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To study the protective mechanism elicited by cystamine, we 
focused on the Homo sapiens heat shock DnaJ-containing protein 1b 
(HSJ1b), which is enriched in the brain. We report that HSJ1b and 
cystamine are neuroprotective in HD by increasing the release of 
brain-derived neurotrophic factor (BDNF) — a trophic factor that 
is depleted in HD brains and is crucial for the survival of striatal 
neurons (24–27) — from neurons both in culture and in animals. 
We demonstrate that cystamine positively regulates BDNF release 
not only by increasing HSJ1 transcripts but also by inhibiting 
TGase. We next show that cysteamine, the FDA-approved reduced 
form of cystamine, is neuroprotective in HD mice by enhancing 
BDNF levels in brain. Indeed, changes in endogenous BDNF lev-
els modulate the cystamine-induced neuroprotective effect in HD 
mice. Finally, BDNF blood levels are low in mice and primate mod-
els of HD and can be increased by injection of cysteamine. Our 
study provides not only new mechanisms by which cystamine pro-
motes neuroprotection in HD, but also a potential new treatment 
for HD using its FDA-approved reduced form, cysteamine.
Results
HSJ1 transcripts are elevated upon cystamine treatment. To confirm that 
cystamine treatment leads to an increase in the amount of HSJ1 
transcripts, we treated mouse immortalized neuronal cells (28) 
with 100 µM cystamine for 24 or 48 hours, lysed the cells, isolated 
mRNAs, and performed real-time quantitative RT-PCR (real-time 
RT-PCR) using validated oligonucleotides (Figure 1A). We observed 
a statistically significant increase in HSJ1 transcripts of 1.7-fold 
after 24 hours treatment and of 2.2-fold after 48 hours (Figure 1A). 
Thus, HSJ1 transcripts are elevated upon cystamine treatment of 
both neuronal cells and the R6/2 mouse model of HD (11).
HSJ1b — the predominant HSJ1 isoform in brain — is decreased in HD 
brains. The HSJ1 gene generates, by alternate splicing, 2 proteins, 
HSJ1a and HSJ1b, that differ in their C termini. HSJ1 mRNAs are 
enriched in brain, and HSJ1a and HSJ1b proteins are found in vari-
ous regions such as cortex, cerebellum, striatum, and retina, with 
HSJ1b more abundant than HSJ1a (Figure 1, B–E) (29). To ana-
lyze the relevance of HSJ1 proteins in the context of HD, we deter-
mined their levels in postmortem samples of striatum from HD 
patients. Striatum that includes caudate nucleus and putamen is 
the most severely affected region in HD (1). By immunoblotting 
the samples with an antibody against HSJ1, we found a dramatic 
decrease in the level of HSJ1b protein in HD patients compared 
with control individuals (Figure 1, C–E). Anti–β-actin was used as 
a control for protein loading. HSJ1a was expressed at low or unde-
tectable levels in both control and HD brain samples. We quanti-
fied the downregulation of HSJ1b and found it to be statistically 
significant (Figure 1F). These results show that the levels of HSJ1b, 
the main isoform of HSJ1 in brain, are reduced in the pathologi-
cal situation and are of further support for a role of HSJ1b in HD 
pathogenesis. The postmortem samples represent late stages of 
the disease. Therefore, such a decrease could be attributed to the 
selective death of neurons expressing HSJ1b. However, these brain 
extracts show no profound modifications in the levels of calbin-
din, a specific marker of medium spiny neurons (data not shown). 
This suggests that the decreased levels of HSJ1b in postmortem 
samples are not merely a reflection of cell death.
HSJ1 proteins protect striatal neurons from polyQ-huntingtin–induced 
cell death. We next investigated whether HSJ1 proteins possess neu-
roprotective properties by studying a neuronal model of HD that 
recapitulates the main features of the disease (24). We transfected 
Figure 1
Cystamine increases HSJ1 transcript levels in 
neuronal cells, while HSJ1b is decreased in 
postmortem brain extracts from HD patients. 
(A) Data revealed a statistically significant 
increase in HSJ1 transcripts induced by cysta-
mine treatment in comparison to control at 24 
hours (Student’s t test, t[21] = 5.77; P < 0.0001) 
and at 48 hours (Student’s t test, t[10] = 9.88; 
P < 0.0001). (B) Protein extracts prepared 
from 1 control human cortical postmortem 
sample and from HEK 293T cells transfected 
with HSJ1a or HSJ1b were immunoblotted 
with an anti-HSJ1 antibody. The major brain 
isoform of HSJ1 proteins was the HSJ1b iso-
form. (C–E) Protein extracts were prepared 
from whole striatum (C), putamen (D), and 
caudate nucleus (E) of control (CT) and HD 
individuals and analyzed as in B. Immunob-
lotting with an anti–β-actin antibody was used 
as a control. (F) Quantification of the West-
ern blots presented in C–E showed a statisti-
cally significant decrease in the protein level 
of HSJ1b in HD samples (n = 12) compared 
with control samples (n = 15) (Student’s t test, 
t[25] = 2.33; P = 0.028). *P < 0.05, #P < 0.0001.
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primary cultures of striatal neurons with constructs encoding the 
first 171 amino acids of huntingtin with 17 (wild-type, 171-17Q-
HA) or 73 glutamines (mutant, polyQ, 171-73Q-HA), either alone 
or in the presence of a construct expressing HSJ1a or HSJ1b, and 
analyzed neuronal death 24 hours after transfection (Figure 2A). 
As expected, the 171-73Q-HA construct induced a statistically sig-
nificant increase in neuronal death compared with the 171-17Q-
HA construct. Interestingly, HSJ1a and HSJ1b decreased neuronal 
death induced by the 171-73Q-HA fragment of huntingtin. These 
findings show that HSJ1 proteins exert a neuroprotective effect on 
polyQ-huntingtin–induced neuronal death.
HSJ1a but not HSJ1b reduces intranuclear inclusions. Hsps are known 
to assist in the refolding of misfolded proteins and/or in the trans-
fer of such proteins to the proteasome for degradation (23, 30). 
Therefore, most Hsps reduce the aggregates in various HD mod-
els (22). Using an aggregation assay (31), we analyzed the effect of 
HSJ1 proteins on the formation of insoluble aggregates induced 
by the 171-73Q-HA fragment of huntingtin (Figure 2B). The DnaJ-
type Hsp40 (HDJ2/HSDJ) was used as a positive control capable 
of solubilizing aggregates (20, 22). Surprisingly, HSJ1a and HSJ1b 
elicited different responses in this assay. Whereas HSJ1a reduced 
insoluble aggregates in a comparable manner to Hsp40, HSJ1b had 
no effect on the solubility of polyQ-huntingtin–induced aggre-
gates. To confirm this differential response in a more physiologi-
cal situation, we transfected primary cultures of striatal neurons 
with 171-73Q-HA and HSJ1a, HSJ1b, or the corresponding empty 
vector and scored the transfected neurons for the presence of NIIs 
(Figure 2C). Again, we found that whereas HSJ1a significantly 
reduced the formation of NIIs, HSJ1b had only a weak effect.
These findings suggest that HSJ1a acts as a “typical” chaperone 
that unfolds misfolded proteins, whereas HSJ1b has a beneficial 
effect on polyQ-huntingtin–induced neuronal death independent 
of polyQ aggregation. As HSJ1a is almost undetectable in brain (Fig-
ure 1), we focused our study on the predominant isoform, HSJ1b.
HSJ1b rescues mutant polyQ dysfunction in Caenorhabditis elegans 
neurons. To test whether HSJ1b may protect against the early 
phases of polyQ-huntingtin–induced neuronal dysfunction in 
vivo, we investigated the effects of HSJ1b in C. elegans transgenics 
that express an exon 1–like N-terminal fragment of huntingtin 
fused to GFP in their touch receptor neurons. This animal model 
of neuronal cell response to polyQ-expanded huntingtin shows 
polyQ-dependent neuronal dysfunction without cell death (32, 
33). We generated transgenic strains of nematodes that express 
human HSJ1b in touch receptor neurons. Four independent sta-
ble lines were crossed with lines stably expressing a GFP-fused 
exon 1–like N-terminal fragment of huntingtin with 19 or 128 
glutamines (exon 1–19Q-GFP or exon 1–28Q-GFP). Quantita-
tive RT-PCR and Western blotting revealed no effect of HSJ1b 
on huntingtin transgene expression and protein levels (Supple-
mental Figure 1; supplemental material available online with 
this article; doi:10.1172/JCI27607DS1). We analyzed the touch 
response of the mutant polyQ and control worms in the absence 
or presence of HSJ1b. As previously reported (32, 33), animals 
expressing exon 1–128Q-GFP presented a statistically significant 
decrease in response to light touch at the tail compared with the 
exon 1–19Q-GFP–expressing worms (Figure 2D). Importantly, 
the loss of touch response induced by exon 1–128Q-GFP was 
inhibited by HSJ1b expression. In contrast, no statistical differ-
ence in cell body aggregation, measured as mean pixel intensity, 
was observed between exon 1–128Q-GFP strains and those with 
HSJ1b coexpression (Figure 2E). We conclude that HSJ1b has 
neuroprotective effects in vitro by inhibiting striatal neuronal 
death and in vivo by reducing neuronal cell dysfunction without 
any major effects on polyQ-huntingtin aggregation.
Figure 2
HSJ1 proteins and polyQ-huntingtin–induced toxicity and dysfunction. (A) Striatal neurons were transfected with 171-17Q-HA or 171-73Q-HA 
and HSJ1a, HSJ1b, or the corresponding empty vectors. Data (ANOVA, F5,40 = 6.89; P < 0.0001) demonstrated that cell death was signifi-
cantly increased by 171-73Q-HA construct (post-hoc Fisher’s test, P < 0.01) and blocked by cotransfection with HSJ1a (post-hoc Fisher’s test, 
P = 0.0043) or HSJ1b (post-hoc Fisher’s test, P < 0.0001). (B) Cell extracts prepared from 171-73Q-HA–transfected HEK 293T cells were 
analyzed by immunoblotting using an anti-HA antibody. (C) Striatal neurons were transfected with 171-17Q-HA or 171-73Q-HA together with 
HSJ1a, HSJ1b, or the corresponding empty vectors. Data (ANOVA, F2,15 = 4.43; P = 0.031) revealed a statistically significant decrease in the 
percentage of neurons with intranuclear inclusions in the presence of HSJ1a (post-hoc Fisher’s test, P = 0.0094) but not of HSJ1b (NS). (D) 
Data (ANOVA, F10,87 = 23.44; P < 0.0001) revealed a statistically significant decrease in mechanosensation of touch receptor neurons in the 
tail of animals expressing the exon 1–128Q-GFP construct compared with neurons expressing exon 1–19Q-GFP (Student’s t test, t[16] = 16.12; 
P < 0.0001). Loss of touch response mediated by exon 1–128Q-GFP was inhibited by expression of HSJ1b (Student’s t test, t[16] = 9.01; 
P < 0.0001). (E) Morphometric analysis revealed no change in the aggregation of fusion proteins in the cell bodies of neurons from HSJ1b-
expressing animals (Student’s t test, t[198] = 1.22; NS). **P < 0.01, #P < 0.001.
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HSJ1b and cystamine promote BDNF release in neuronal cells. How 
does HSJ1b promote neuronal survival? Little is known about 
the function of HSJ1 proteins. We do know, however, that they 
interact with the Hsp70 family of proteins and stimulate their 
ATPase activity to regulate their substrate-binding capacities (34). 
Also, HSJ1 proteins inhibit the heat shock cognate 70 kDa (hsc70) 
protein. Since hsc70 is a constitutive Hsp70 that removes clathrin 
from clathrin-coated vesicles (CCVs), we hypothesized that HSJ1 
proteins might play a role in regulating intracellular trafficking 
of CCVs (35). Indeed, huntingtin itself is implicated in clathrin-
mediated endocytosis; it interacts with several proteins involved 
in this process, including HIP1, HIP12, PACSIN1, SH3GL3, and 
HIP14 (for a review, see ref. 36), and we recently demonstrated 
that huntingtin acts as a processivity factor to promote micro-
tubule-based intracellular transport of BDNF-containing vesicles 
(27). In addition, the intracellular trafficking of BDNF-contain-
ing vesicles is altered, resulting in a decreased release of BDNF 
and subsequent neuronal toxicity.
We therefore analyzed whether HSJ1b protein regulates BDNF 
release in neuronal cells. To make sure that any effect on BDNF 
release was not due to a defect in BDNF transcription, we ectopi-
cally expressed BDNF under the control of the CMV promoter. In 
addition, the levels of BDNF in the supernatant were normalized 
to BDNF levels in cell lysates. Mouse neuronal cells were lipofected 
with vectors expressing BDNF, HSJ1b or HSJ1a, or the correspond-
ing empty vector, and the amount of BDNF in the supernatant 
was assessed by ELISA (Figure 3A). Strikingly, HSJ1b significantly 
increased the amount of BDNF released, whereas HSJ1a had no 
effect. These results suggest that HSJ1b promotes neuronal sur-
vival by enhancing BDNF release in neuronal cells.
We next examined whether the effect of HSJ1b could be reca-
pitulated by cystamine. Treating cells with cystamine for varying 
lengths of time led to increased BDNF release (Figure 3B). We also 
analyzed the amount of BDNF in cell lysates and supernatants by 
standard Western blotting (Figure 3C). While the levels of BDNF 
were similar in cell lysates, 24 and 48 hours of cystamine treat-
ment resulted in increased BDNF release. These findings show 
that HSJ1b and cystamine increase BDNF release in neuronal cells. 
This effect was specific to HSJ1b, as HSJ1a did not modify BDNF 
release under the same conditions.
To determine whether the effect of cystamine on BDNF secre-
tion requires HSJ1b, we used an RNA interference approach. We 
transfected neuronal cells with pSUPER-RNAi-HSJ1, which targets 
both HSJ1a and HSJ1b, as we could not identify RNAi discriminat-
ing between the 2 isoforms (data not shown). We used RT-PCR to 
demonstrate that pSUPER-RNAi-HSJ1 reduced HSJ1 mRNA levels 
(Figure 3D). Strikingly, the ability of cystamine to increase BDNF 
release was lost in pSUPER-RNAi-HSJ1–transfected cells (Figure 
3E) showing that the effect of cystamine on BDNF release requires 
HSJ1 proteins. As HSJ1a is almost undetectable in brain and has 
no effect on BDNF secretion (Figure 3A), the results of this experi-
ment strongly support the notion that at least part of the effect of 
cystamine on BDNF release involves HSJ1b.
HSJ1b stimulates the secretory pathway. Clathrin is the main com-
ponent of the protein coats that decorate the cytoplasmic face of 
vesicles budding from the plasma membrane, the trans-Golgi net-
work (TGN), and endosomes (37). The clathrin coat is, therefore, 
an important target for regulating secretion and endocytosis. To 
understand how HSJ1b and cystamine might act through clath-
rin to promote BDNF release, we first analyzed the distribution 
of HSJ1b, BDNF, and clathrin by performing subcellular fraction-
ation of neuronal cells expressing HSJ1b and BDNF-GFP con-
structs (Figure 4A). We found that these 3 proteins are enriched 
in the P3 fraction corresponding to small vesicles, confirming the 
distribution of BDNF and cofractionating with huntingtin (27). 
We also purified CCVs and found they were enriched in HSJ1b and 
Figure 3
HSJ1b and cystamine increase BDNF release. (A) Neuronal cells were transfected with BDNF, HSJ1a, HSJ1b, or the corresponding empty 
vectors. Forty-eight hours after transfection, cells were washed with PBS and incubated for 30 minutes with DMEM, and supernatants (super.) 
were collected. Data (ANOVA, F2,31 = 9.17; P = 0.0007) revealed that HSJ1b (post-hoc Fisher’s test, P = 0.0002), but not HSJ1a (NS), induced 
a statistically significant increase in BDNF release. (B) Data (ANOVA, F3,39 = 323.66; P < 0.0001) revealed a statistically significant increase in 
BDNF content in the supernatant of 100 µM cystamine-treated cells at 24, 48, and 72 hours (post-hoc Fisher’s test, P < 0.0001). (C) Cells trans-
fected with BDNF and treated with cystamine were analyzed by immunoblotting with anti-BDNF and anti–β-actin antibodies. (D) Data (ANOVA, 
F3,29 = 26.01; P < 0.0001) revealed a statistically significant decrease in HSJ1 transcripts in cells transfected with siRNA-HSJ1 compared with 
control cells with or without cystamine treatment (post-hoc Fisher’s test, P < 0.0001). Cystamine increased HSJ1 transcripts in control conditions 
(post-hoc Fisher’s test, P = 0.002) but not in the presence of siRNA-HSJ1 (NS). (E) Cystamine did not increase BDNF release when HSJ1b levels 
were lowered by RNAi-HSJ1 (ANOVA, F3,19 = 7.59; P = 0.0016). Cells were cotransfected with BDNF and pSUPER-RNAi-HSJ1 and treated with 
cystamine 48 hours after transfection. There was a significant increase in BDNF release in cystamine-treated cells compared with control cells 
(post-hoc Fisher’s test, P = 0.0005). **P < 0.01, #P < 0.001.
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BDNF. In addition, we found HSJ1b colocalizing with GMAP-210, 
a marker of the cis-Golgi (Figure 4B) (38) and with BDNF (Figure 
5E). These results are consistent with a role for HSJ1b in the regu-
lation of BDNF processing in the secretory pathway.
Since HSJ1b is known to regulate clathrin coating in vitro, we 
analyzed by immunofluorescence microscopy the subcellular loca-
tion of BDNF relative to the location of endogenous clathrin (Fig-
ure 4C, upper panels). BDNF-containing vesicles and clathrin were 
both found predominantly in the Golgi region (as identified by 
immunostaining for GM130, another cis-Golgi marker; Figure 4C 
and data not shown). Increasing the levels of HSJ1b enhanced the 
colocalization of BDNF and clathrin, whereas reducing HSJ1b pro-
Figure 4
HSJ1b increases BDNF processing from the Golgi to the cytoplasm. (A) BDNF, clathrin, and HSJ1b were present in the same cellular compart-
ments: small vesicle fraction (P3) and CCV fraction (p). (B) HSJ1b partially colocalized with the Golgi apparatus. (C) HSJ1b enhanced colocaliza-
tion between BDNF and clathrin in the Golgi region, whereas RNAi-HSJ1 disrupted it. Scale bars: 10 µm. (D) Quantification (ANOVA, F3,64 = 7.71; 
P = 0.0002) revealed that expression of HSJ1b significantly increased the amount of BDNF vesicles that were clathrin positive compared with 
control cells (post-hoc Fisher’s test, P = 0.032), while pSUPER-RNAi-HSJ1 significantly decreased it (post-hoc Fisher’s test, P = 0.019). Over-
expression of HSJ1a had no effect (NS). (E) Scheme showing the measurement of BDNF in the Golgi area (left) and in the cytoplasm (sorted 
vesicles, right). (F) Quantification (ANOVA, F3,67 = 2,92; P = 0.04) revealed that lowering HSJ1b by interference significantly decreased BDNF 
content in the Golgi area (post-hoc Fisher’s test, P = 0.005). There was no difference between cells expressing HSJ1b or HSJ1a compared with 
control conditions (NS). (G) Quantification (ANOVA, F3,47 = 5,84; P = 0.0018) revealed that HSJ1b increased the amount of BDNF vesicles in 
the cytoplasm in comparison to control cells (post-hoc Fisher’s test, P = 0.048), whereas pSUPER-RNAi-HSJ1 decreased it (post-hoc Fisher’s 
test, P = 0.038). The difference was not significant in HSJ1a-overexpressing cells (NS). *P < 0.05, **P < 0.01.
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tein levels by RNA interference dramatically decreased it (Figure 
4C, middle panels). Interestingly, decreasing HSJ1b protein levels 
also had an important impact on the intracellular distribution of 
clathrin, which appeared randomly distributed in the cytoplasm. 
HSJ1a had little or no effect on the colocalization of BDNF and 
clathrin. By quantifying the overlap between BDNF and clathrin, 
we found these effects to be statistically significant (Figure 4D). 
This increase in the clathrin coating of BDNF-containing vesicles 
in response to overexpression of HSJ1b is consistent with the fact 
that HSJ1b inhibits hsc70-catalyzed clathrin uncoating (35).
To understand how an increase in the clathrin coating of BDNF 
vesicles leads to an increase in the release of BDNF from neuronal 
cells, we measured the sorting of BDNF from the Golgi/TGN 
region into the cytoplasm by image analysis. We quantified the 
Figure 5
Cystamine and TGase 2 regulate BDNF secretion. (A) Cystamine treatment (100 µM, 30 minutes) of BDNF-GFP–transfected cells decreased 
colocalization between BDNF and GM130. BFA dispersed BDNF vesicles and GM130 with or without cystamine. (B) Quantification (ANOVA, 
F2,46 = 7.10; P = 0.0021) revealed that cystamine significantly decreased BDNF in the Golgi area compared with control cells at 30 minutes 
(post-hoc Fisher’s test, P = 0.011) and 2 hours (post-hoc Fisher’s test, P = 0.0007). (C) Data (ANOVA, F2,46 = 4.83; P = 0.0125) revealed that 
cystamine treatment significantly increased BDNF content in cytoplasmic vesicles compared with control cells at 30 minutes (post-hoc Fisher’s 
test, P = 0.021) and 2 hours (post-hoc Fisher’s test; P = 0.0049). (D) Data (ANOVA, F3,32 = 45.6; P < 0.0001) revealed that BFA significantly 
reduced BDNF release in control and cystamine-treated cells (post-hoc Fisher’s test, P < 0.0001). Cystamine had an effect on control (post-hoc 
Fisher’s test, P < 0.006) but not on BFA-treated cells (NS). (E) TGase 2 colocalization with HSJ1b at the Golgi (GMAP-210) was disrupted in 
pSUPER-RNAi-HSJ1–transfected cells. (F) TGase overexpression induced a decrease in cytoplasmic BDNF-containing vesicles. Scale bars: 
10 µm. (G) TGase 2 did not modify BDNF content in the Golgi area compared with control cells (Student’s t test, t[13] = 0.4; NS). (H) TGase 2 
induced a statistically significant decrease in cytoplasmic BDNF vesicles compared with control cells (Student’s t test, t[13] = 3.4; P = 0.0051). 
*P < 0.05, **P < 0.01, and #P < 0.001.
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intensity of the BDNF signal in the Golgi region (Figure 4E, left) 
and the number of cytoplasmic BDNF-containing vesicles of 67 
nm–3.35 µm diameter (1–50 pixels) that correspond to vesicles 
budding from the Golgi/TGN region (Figure 4E, right). Reduc-
ing HSJ1 by RNA interference induced a statistically significant 
decrease in the BDNF content in the Golgi region (Figure 4F) and 
in the number of budding vesicles (Figure 4G). By contrast, HSJ1b 
overexpression increased the number of BDNF-containing vesicles 
in the cytoplasm. These findings indicate that HSJ1b is required 
for the formation of BDNF-containing vesicles.
Cystamine promotes BDNF secretion by an HSJ1b-dependent mecha-
nism involving TGase inhibition. We have demonstrated that cysta-
mine and HSJ1b increase BDNF release from neuronal cells and 
that the cystamine-induced BDNF release requires HSJ1b. We next 
treated neuronal cells with cystamine and analyzed the sorting of 
BDNF vesicles from the Golgi (Figure 5A). Analysis of 15–20 cells 
revealed that cystamine induced an extensive depletion of BDNF 
from the Golgi apparatus (Figure 5B) and increased the BDNF 
content of the vesicles (Figure 5C). These results indicate that cys-
tamine promotes BDNF secretion by increasing the load of the 
neurotrophic factor in vesicles.
To verify that cystamine affects the secretion from the Golgi, we 
used brefeldin A (BFA), a fungal metabolite that is a potent inhibi-
tor of Golgi vesicle fusion (39). BFA treatment led to dispersion 
of BDNF vesicles and, as expected, of the Golgi marker GM130 
and was unaffected by cystamine treatment (Figure 5A, lower pan-
els). We next analyzed BDNF release by ELISA in these conditions 
(Figure 5D). Strikingly, the ability of cystamine to increase BDNF 
release was lost in BFA-treated cells, demonstrating that the effect 
of cystamine on BDNF release requires secretion from the Golgi.
Because cystamine is well known to inhibit TGase in vitro, we 
tested the possibility that TGase might play a role in BDNF secre-
tion. Several isoenzymes of TGase are found in the brain, of which 
TGase 2 is the most abundant. We found that TGase 2 partially 
colocalized with GMAP-210, with HSJ1b, and with BDNF (Figure 
5E, upper and middle panels). We next analyzed whether TGase 2 
localization depends on HSJ1b. Interestingly, reducing HSJ1b lev-
els by RNA interference modified TGase 2 localization at the Golgi 
(Figure 5E, lower panels) and disrupted the Golgi (data not shown). 
We also assessed the consequences of increased TGase 2 activity on 
BDNF secretion. Cells were transfected with TGase 2 and treated 
with glutamate (5 µM, 30 minutes) to increase intracellular cal-
cium concentration and subsequently activate the enzyme (40). 
In these conditions, BDNF remained in the Golgi area, whereas 
the number of BDNF-containing vesicles in the cytoplasm was 
reduced (Figure 5, F–H). These results demonstrate that TGase 
2 inhibits BDNF processing. This observation is consistent with 
a report showing that TGase inhibitors stimulate catecholamine 
release from rat brain synaptosomes (41).
We have shown that cystamine induces BDNF release by increasing 
its processing from the Golgi/TGN region. We propose that cysta-
mine acts at 2 levels: first, it stimulates the transcription of HSJ1b 
that is required for the sorting of BDNF-containing vesicles and sec-
ond, it also increases BDNF processing by inhibiting TGase activity.
HSJ1b and cystamine rescue BDNF release defects induced by polyQ-
huntingtin in cells and in HD mice. We determined the effect of HSJ1b 
and cystamine on BDNF release in the pathological situation. We 
used mouse neuronal cells derived from knock-in mice in which a 
109-CAG expansion, encoding 109 glutamine residues, was insert-
ed into the endogenous mouse huntingtin gene (109Q/109Q) (28). 
This cell line closely resembles the situation in HD patients as, in 
these cells, polyQ-huntingtin is expressed at endogenous levels. 
The level of BDNF released from these cells into the supernatant 
was significantly lower in 109Q/109Q cells compared with wild-
Figure 6
HSJ1b, cystamine, and cysteamine regulate BDNF levels in HD. (A) 
BDNF release was decreased (ANOVA, F3,33 = 17.45; P < 0.0001) 
in 109Q/109Q cells compared with control cells (post-hoc Fisher’s 
test, P < 0.0001). This decrease was rescued when cells were trans-
fected with HSJ1b (post-hoc Fisher’s test, P < 0.0001) or treated 
with 100 µM cystamine for 30 minutes (post-hoc Fisher’s test, 
P = 0.001). (B) Data (ANOVA, F2,29 = 3.63; P = 0.0392) revealed a 
statistically significant increase in the amount of BDNF in the brains 
of mice treated with cystamine (post-hoc Fisher’s test, P = 0.015) 
or with cysteamine (post-hoc Fisher’s test, P = 0.04) compared with 
controls. (C) Data (ANOVA, F3,49 =11.66; P < 0.0001) revealed a 
statistically significant increase in the amount of BDNF in the brains 
of mice treated with cysteamine (post-hoc Fisher’s test, P < 0.001). 
(D) Cysteamine increased BDNF levels in the striatum of the differ-
ent genotypes (ANOVA, F5,14 = 9.20; P < 0.0004): wild-type animals 
(post-hoc Fisher’s test, P = 0.002); bdnf+/+httm mice (R6/1mice; post-
hoc Fisher’s test, P = 0.009); and bdnf+/–httm mice (post-hoc Fisher’s 
test, P = 0.024). *P < 0.05, **P < 0.01, and #P < 0.001.
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type neuronal cells (Figure 6A). Interestingly, ectopic expression of 
HSJ1b or treatment with cystamine increased BDNF release from 
109Q/109Q cells. Thus, the defect in BDNF release in a cellular 
model of HD can be rescued by HSJ1b or cystamine.
We next investigated whether cystamine regulates BDNF levels in 
the brain by injecting mice daily with cystamine. Mice were sacri-
ficed after 7 days of treatment (30 minutes after the last injection), 
and the BDNF levels in brain extracts were measured. Treatment 
with cystamine resulted in an increase in brain BDNF level (Fig-
ure 6B). We also assessed in vivo the effect of the reduced form of 
cystamine, cysteamine. Unlike cystamine, cysteamine is an FDA-
approved drug that is used to treat a rare childhood disorder called 
cystinosis (42), and tolerability of cysteamine was determined in HD 
patients (43, 44). Therefore, cysteamine might be used immediately 
after appropriate phase II clinical studies for use in HD patients. We 
analyzed the ability of cysteamine in comparison to cystamine to 
increase BDNF levels in the brain of treated mice and observed that 
cysteamine recapitulated the positive effect of cystamine on BDNF 
secretion in animals (Figure 6B). Having shown that cystamine and 
cysteamine are effective in wild-type mice, we tested the ability of 
cysteamine to regulate BDNF release in knock-in mice carrying a 
109Q repeat in the Hdh locus that are homozygous for the mutation 
(45). We observed a small but not significant reduction (P = 0.096) 
in the brain levels of BDNF in Hdh109Q/109Q mice compared with their 
wild-type littermates (Figure 6C). Interestingly, cysteamine induced 
a significant increase in BDNF levels in HD knock-in mice.
Figure 7
Cysteamine is neuroprotective in HD mice through a BDNF-dependent mechanism. (A) In situ hybridization revealed that ENK mRNA were 
reduced in R6/1 (bdnf+/+httm) and dramatically reduced in bdnf+/–httm mice. At early stages, cysteamine treatment increased the levels of ENK 
mRNA in bdnf+/+httm and in bdnf+/–httm mice. (B) Quantification of ENK mRNA levels. WT-sham, wild-type saline-treated mice. (C) Cysteamine 
treatment of wild-type animals did not modify DARPP-32 immunostaining. In R6/1 animals, there was a decrease in the number of DARPP-32– 
positive cells that was recovered by cysteamine treatment. The loss of DARPP-32–positive neurons could not be prevented by cysteamine treat-
ment in bdnf+/–httm mice. Scale bar: 50 µm. (D) Quantitative analysis of the changes in DARPP-32 immunostaining. *P < 0.05, **P < 0.01, and 
#P < 0.001; see statistical analysis in Methods.
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Cysteamine is neuroprotective in R6/1 mice by increasing BDNF levels. 
Strong evidence indicates that cystamine is neuroprotective in 
HD mouse models (10, 11, 14, 15). We aimed to assess whether 
cysteamine is neuroprotective in vivo and whether this depends 
on BDNF. For this purpose, we used a mouse model of HD, R6/1 
mice, which show	a much faster progression of disease phenotype 
compared with Hdh109Q/109Q mice (46, 47) and a double mutant line 
previously generated by crossing R6/1 mice with bdnf heterozygous 
mice (26). We first investigated whether cysteamine regulates BDNF 
levels in the striatum by injecting wild-type, R6/1 (bdnf +/+httm), 
and double mutant mice (bdnf+/–httm) daily for 7 days (Figure 6D). 
Although less efficiently in bdnf+/–httm mice, this treatment induced 
an increase in striatal BDNF levels in the 3 mouse genotypes.
We next analyzed the effect of cysteamine treatment in differ-
ent neuronal populations in these HD models at early (16 weeks) 
and late (26 weeks) stages of 
the disease. At 16 weeks, R6/1 
mice are still presymptom-
atic, while double mutant 
(bdnf +/–httm) mice already have 
a motor behavioral impair-
ment. We analyzed the mice for 
enkephalin, a specific marker 
for striatopallidal neurons 
that are affected early in HD, 
and substance P, a marker for 
striatonigral neurons. At this 
early stage, enkephalin mRNA 
levels were not highly affected 
in R6/1 mice, whereas a much 
greater reduction was observed 
in bdnf+/–httm mice (Figure 7, A 
and B) (26). Administration of 
cysteamine in double mutant 
mice increased the expression 
of enkephalin above the lev-
els in sham-R6/1 and sham-
bdnf +/–httm mice. Cysteamine 
treatment did not modify the 
number of substance P–posi-
tive neurons in R6/1 mice or in 
double mutant mice above that 
in control mice (Supplemental 
Figure 2). These data show that 
cysteamine is neuroprotective 
in R6/1 mice at early stages.
We next determined changes 
in dopamine and cAMP-regu-
lated phosphoprotein of a 
molecular mass of 32 kDa 
(DARPP-32), a specific marker 
for striatal projection neurons 
that is affected at the age of 26 
weeks, but not at 16 weeks, in 
R6/1 mice. As expected, at 26 
weeks, a decrease in DARPP-32–
positive cells was observed in 
R6/1 compared with wild-type 
mice (Figure 7C). Interestingly, 
whereas cysteamine treatment 
prevented the reduction in the number of DARPP-32–positive cells 
in R6/1 mice, this treatment had no effect in R6/1 mice with dis-
ruption of bdnf (bdnf +/–httm mice). We quantified these changes and 
found them to be statistically significant (Figure 7D).
Taken together, the results of experiments using enkephalin and 
DARPP-32 markers indicate that cysteamine is also neuroprotective 
in HD mice. This effect is similar to that of exogenous BDNF admin-
istration (26). Furthermore, these data demonstrate that this neuro-
protective effect is dependent on the levels of endogenous BDNF.
Cystamine and cysteamine increase blood levels of BDNF in rodent and 
primate models of HD. We explored whether the positive effect of 
cystamine and cysteamine on BDNF secretion can also be seen in 
peripheral tissues. As with brain extracts, we observed a similar 
increase in BDNF levels in the blood of mice treated with cystamine 
or with cysteamine (Figure 8A). We next asked whether such chang-
Figure 8
Cysteamine increases blood levels of BDNF in rodents and in a primate HD model. (A) Data (ANOVA, 
F2,27 =17.13; P < 0.0001) revealed that the amount of BDNF in serum of mice treated with cystamine (post-
hoc Fisher’s test, P < 0.0001) or with cysteamine (post-hoc Fisher’s test, P < 0.0001) was significantly 
increased. (B) The blood level of BDNF (ANOVA, F3,50 =17.22; P < 0.0001) was reduced in Hdh109Q/109Q 
mice compared with wild-type littermates (post-hoc Fisher’s test, P = 0.0001) and rescued by cysteamine. 
The amount of BDNF in the serum of wild-type mice (post-hoc Fisher’s test, P = 0.0099) and Hdh109Q/109Q 
mice (post-hoc Fisher’s test, P = 0.0010) was increased upon cysteamine treatment. (C) There was an 
increase of BDNF in serum of 4 cysteamine-treated rats (ANOVA, F10,64 = 9.29; P < 0.0001) after 45 minutes 
(post-hoc Fisher’s test, P < 0.0001) and 60 minutes (post-hoc Fisher’s test, P < 0.0001). (D) BDNF levels 
were reduced in the blood of 3NP-treated monkeys (Student’s t test, t[27] = 3.05; P = 0.005). **P < 0.01 and 
#P < 0.001. Data are from 4 controls and three 3NP-treated monkeys. (E and F) Blood BDNF levels were 
increased in HD monkeys injected with cysteamine. (E) Representative results for 1 monkey are shown. (F) 
Graph represents the results for the 2 injected monkeys. Error bars represent SEM.
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es can be seen in Hdh109Q/109Q mice (Figure 8B). The blood of mice for 
which brain BDNF levels were measured (Figure 6C) was analyzed. 
Interestingly, a much greater reduction in the level of BDNF was 
detected in the serum of Hdh109Q/109Q mice compared with wild-type 
mice. As for brain levels, cysteamine also increased BDNF levels in 
Hdh109Q/109Q mice. We next characterized the pharmacokinetics of 
cysteamine’s effect on BDNF levels in the blood of rats injected 
with cysteamine (Figure 8C). As in mice, blood BDNF levels also 
increased in response to cysteamine in rats. The maximum increase 
was reached 45–60 minutes after cysteamine administration, and 
BDNF levels returned to basal level after 90 minutes.
To further explore the effect of cysteamine in a situation that is 
close to human pathology, we chose a nonhuman primate model of 
HD produced by chronic systemic administration of the mitochon-
drial complex II inhibitor 3–nitropropionic acid (3NP). Chronic 
3NP treatment produces striatal dysfunction and neurodegenera-
tion in primates, leading to abnormal movements (including chore-
iform movements and dystonia) and frontal-type cognitive deficits 
that are highly reminiscent of HD (48, 49). We first asked whether 
BDNF levels were altered in the blood of 3NP-treated primates. We 
analyzed blood samples from 3NP-treated long-tailed macaques 
and observed a statistically significant decrease in peripheral BDNF 
when compared to control animals (Figure 8D).
Having shown that peripheral BDNF is decreased, we tested 
whether systemic injection of cysteamine would enhance BDNF 
levels in the primate model of HD. In two 3NP-treated macaques, 
we found that acute injection of cysteamine (100 mg/kg) rapidly 
induced an increase in BDNF blood levels (Figure 8, E and F). As in 
rats, the blood levels of BDNF peaked around 30 minutes after cys-
teamine injection and progressively returned to normal within 60 
minutes, consistent with a transient but massive increase in BDNF 
release into the plasma compartment. This demonstrates that in a 
primate model of HD, BDNF peripheral levels are decreased and 
can be increased by administration of cysteamine.
Discussion
Cystamine is one of the very few candidate drugs being considered 
for the treatment of HD. Here we have investigated the molecular 
mechanisms of action of cystamine, and our study has revealed that 
an FDA-approved reduced form of cystamine produces very similar 
biological effects in vitro and in vivo. We demonstrate that part of 
the neuroprotective effect of cystamine is due to its promotion of 
secretion of the neuronal survival factor BDNF. Cystamine has 2 
quite distinct actions in this regard. First, it increases the steady-
state levels of the Hsp HSJ1b mRNA, which stimulates the secre-
tory pathway through its action on CCV formation, and, second, it 
inhibits TGase, which has a negative effect on BDNF sorting.
HSJ1b belongs to the large family of DnaJ-like proteins that con-
tain the typical Hsp40 chaperones HDJ1/Hsp40 and HDJ2/HSDJ. 
In most cases, these chaperones have been reported to reduce polyQ-
induced aggregation and toxicity in various models (for reviews, see 
refs. 20–22). We found that HSJ1b functions in a qualitatively dif-
ferent way inasmuch as it appears not to prevent aggregation or the 
formation of NIIs. However, we found that HSJ1b is relevant to HD, 
as it strongly inhibits polyQ-huntingtin–induced neuronal death 
in vitro and rescues neuronal dysfunction in a nematode model of 
HD. Although we found that in mammalian cells, HSJ1b stimulates 
BDNF secretion, the exact mechanism by which HSJ1b operates in 
nematodes remains to be established. Indeed, BDNF is absent in 
nematodes. HSJ1b could, however, enhance the secretion of other 
specific C. elegans factors. In C. elegans, trophic factors other than 
BDNF exist. In particular, the mesencephalic, astrocyte-derived neu-
rotrophic factor, MANF, is well conserved from C. elegans to humans 
and could be the target of HSJ1b (50). Furthermore, BDNF second 
messengers are conserved. Therefore, it is possible that HSJ1b acts 
through a pathway involving these molecules.
In mammalian cells the neuroprotective properties of HSJ1b are 
linked to its ability to enhance neurotrophic support. HSJ1b posi-
tively regulates the sorting of BDNF-containing vesicles from the 
Golgi/TGN, leading to an increase in BDNF release. These find-
ings are in agreement with the function of HSJ1b in the inhibition 
of the uncoating of CCVs (35). Most of the vesicles budding from 
the Golgi/TGN region are CCVs, and assembly of the clathrin coat 
on the forming bud is an important step (37). HSJ1b could there-
fore promote the budding of BDNF-containing vesicles by stabi-
lizing this assembly step. Consistent with this idea, we observed 
an increased percentage of BDNF-containing vesicles that were 
clathrin positive when HSJ1b expression was increased, whereas 
reducing HSJ1b levels decreased it. Interestingly, we found signifi-
cantly less HSJ1b in postmortem brain extracts from HD patients 
than from control brains, suggesting a potential alteration in the 
processing of BDNF at the Golgi/TGN during HD pathogenesis. A 
defect in clathrin coating processes in HD is supported by the fact 
that huntingtin interacts with HIP1 and HIP12/HIP1R, 2 proteins 
that are components of clathrin coats and that regulate clathrin 
assembly by directly interacting with clathrin (51, 52). HSJ1b is 
thought to inhibit uncoating by interfering with the interactions 
of Hsc70 with specialized uncoating DnaJ-like proteins such as 
auxilin (35). Whether it also regulates the activity of huntingtin 
interactors such HIP1 remains to be determined.
The second consequence of cystamine treatment is promotion 
of the secretion of BDNF vesicles through a mechanism involv-
ing TGase. Our findings that TGase 2 colocalizes with BDNF at 
the Golgi and the observation that TGases regulate the secretion 
of BDNF is consistent with previous observations from the 1980s 
indicating a role of TGases in inhibiting secretion and/or release 
of various hormones and neurotransmitters such as insulin, sero-
tonin, and dopamine (41, 53, 54). For instance, monodansylca-
daverine (MDC), a potent TGase inhibitor, enhances dopamine 
release from rat brain synaptosomes in basal and in potassium-
stimulated conditions (41). Moreover, reports that MDC blocks 
clathrin-mediated endocytosis (55, 56) accord with our finding 
that cystamine and TGases regulate the clathrin pathway.
We and others have reported a lack of BDNF support in HD that 
involves defects in BDNF synthesis (25) and transport (27). Our 
findings suggest that, in addition, a defect in BDNF sorting from 
the Golgi/TGN occurs in HD and that such BDNF processing is 
regulated by HSJ1b and TGases.
Cystamine was first described as a TGase inhibitor in vitro, and 
several studies are consistent with the possibility that cystamine 
is beneficial in HD by this mechanism (10, 11, 14, 15). However, 
whether cystamine is directly inhibiting TGase 2 in vivo remains 
to be clearly established. First, the reduced form of cystamine, cys-
teamine, could act as a competitive inhibitor of TGase 2 in vivo 
(57). Second, other metabolites of cystamine and cysteamine could 
mediate the neuroprotective effect, as they are rapidly metabolized 
and low to undetectable levels of cystamine and cysteamine are 
found in the brain of cystamine-treated mice (17). In addition, 
cystamine or its metabolites could act through a TGase-indepen-
dent mechanism (16). Cystamine inhibits caspase 3 activity and 
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increases glutathione levels in cells (18). In vivo, the beneficial 
effect of cystamine could involve the increase in l-cysteine, which 
has antioxidant properties (17, 19).
We now show that cystamine and cysteamine target HSJ1b 
and TGase to increase the release of BDNF, a trophic factor that 
is depleted in HD and that is crucial for the survival of striatal 
neurons in HD. Our data further emphasize that cystamine or its 
metabolites acts at multiple levels to protect against polyQ-hun-
tingtin–induced toxicity and therefore add to the motivation for 
optimizing a therapy with cystamine or related compounds.
We demonstrate that cysteamine is as efficient as cystamine in 
increasing levels of BDNF in the brain. We also report that cyste-
amine is neuroprotective in HD mice by increasing levels of BDNF 
in brain. BDNF levels can also be measured in blood as a biomarker 
for pathological stages. We found that in HD knock-in mice and in 
a primate model of HD, the levels of BDNF in serum were reduced 
compared with those in controls, whereas such decreases in brain 
BDNF could not be detected in HD knock-in mice and in R6/1 mice 
at 15 and 16 weeks of age. Interestingly, at these early stages, these 
mice do not show overt phenotypes (45, 46). This suggests that 
blood BDNF could be used to follow disease progression and vali-
date the neuroprotective effects of drugs acting on BDNF levels.
We found cysteamine-induced release of BDNF in brain to be 
transient. This is consistent with the rapid clearance of cysteamine 
from the plasma of healthy individuals (58) and patients with 
nephropathic cystinosis (59) and suggests that, as for the treat-
ment of nephropathic cystinosis, repeated doses of cysteamine 
at short intervals would be appropriate for the treatment of HD. 
Such limited and controlled release of BDNF is of particular inter-
est for therapy, as an excessive stimulation of the BDNF/TrkB 
pathway leads to tumorigenesis in mice (60). Moreover, the effi-
cacy of a repeated treatment is unlikely to diminish with time, as 
we found that the cysteamine-induced increase in brain and serum 
BDNF levels was still detected after 12 weeks continuous treat-
ment (Supplemental Figure 3).
We propose the use of cysteamine as a therapeutic approach to 
treat HD. Indeed, the safety of cysteamine in humans is well docu-
mented, as cysteamine is used to treat cystinosis (42, 61). Moreover, 
the tolerated cysteamine dose has been evaluated in HD patients 
(43, 44). Finally, our findings indicate that the efficacy of cyste-
amine treatment in HD patients could be monitored by measuring 
serum levels of BDNF as a convenient biomarker.
Methods
Constructs. The vectors encoding BDNF, BDNF-GFP, Hsp40, and TGase 2 
have been described previously (62–64). The 171-17Q-HA and the 171-
73Q-HA were obtained by inserting an HA tag into the XhoI-XbaI sites of 
the pcDNA-171-17Q and pcDNA-171-73Q, respectively (24). The oligo-
nucleotides used were: 5′-TCGAGTACCCATACGATGTTCCAGATTAC-
GCTTAAT-3′ and 5′-CTAGATTAAGCGTAATCTGGAACATCGTATGGG-
TAC-3′. The BamHI inserts of pBPSTR-1-HSJ1a and of pBPSTR-1-HSJ1b 
contained the sequences encoding human HSJ1a and HSJ1b, respectively 
(29), and were subcloned into the pcDNA3 vector (Invitrogen Corp.).
The RNA sequence targeting mouse HSJ1 corresponds to the cod-
ing region 97–116 (GenBank accession number NM178055). The 
pSUPER-RNAi-HSJ1 construct was generated by inserting in the BbsI 
cloning site of pSuperhH1Neo (InvivoGen) the following annealed oli-
gonucleotides: 5′-CAAAAAGACAAGAACCCGGATAATAGGTGGTAT-
TATCCGGGTTCTTGT-3′ and 5′-TCCCGACAAGAACCCGGATAATAC-
CACCTATTATCCGGGTTCTTGTCTT-3′.
Real-time RT-PCR. Forty-eight hours after transfection, neuronal cells 
(wild-type; ref. 28) were treated with 100 µM cystamine (Sigma-Aldrich) 
for 24 or 48 hours and lysed in TRIzol (Invitrogen Corp.). Total RNA 
was extracted, and samples were retrotranscribed using the First-Strand 
cDNA Synthesis Kit (Amersham Biosciences). cDNAs were then diluted 
1:400 and submitted to RT-PCR (iQ SYBR Green Supermix; Bio-Rad) with 
the following HSJ1 oligonucleotides corresponding to the mouse coding 
region 1272–1387 (GenBank accession number NM178055): 5′-TCAG-
GCCCCTTCTTTACCTT-3′ and 5′-AAGGGTCTCCACTCCCAAAAG-3′. 
HPRT gene was used as an internal control and quantified with the follow-
ing oligonucleotides: 5′-CACAGGACTAGAACACCTGC-3′ and 5′-GCTG-
GTGAAAAGGACCTCT-3′.
Results were analyzed using the ICycler apparatus (Bio-Rad). Data are 
from 4 separate quantitative RT-PCR experiments performed in triplicate 
from 2 independent mRNA preparations.
Human tissues. Human tissue samples 1–5 were from the Harvard Brain 
Tissue Resource Center (HBTRC) and correspond to brain numbers 4741, 
4744, 4751, 4797, and 4740 as numbered by the HBTRC. Samples 1–3 
were controls (age: 55.3 ± 1.9 years; postmortem delay: 23.8 ± 1.9 hours 
[mean ± SEM]). Samples 4 and 5 were from grade 3 and 4 HD brains, 
respectively (age: 63.5 ± 18.5 years; postmortem delay: 24.0 ± 2.0 hours). 
Human brain samples 6–27 were collected at the Salpêtrière. Samples 
6–10 were putamen from controls (age: 72.6 ± 8.9 years; postmortem 
delay: 9.4 ± 2.1 hours). Samples 11–15 were putamen from symptomatic 
HD patients with family history (age: 65.6 ± 3.7 years; postmortem delay: 
26.5 ± 7.4 hours). Samples 16–22 were caudate samples from controls (age: 
79.4 ± 1.7 years; postmortem delay: 13.8 ± 3.0 hours). Samples 23–27 were 
caudate samples obtained from symptomatic HD patients with family his-
tory (age: 65.0 ± 4.0 years; postmortem delay: 25.2 ± 7.4 hours).
Brain samples were homogenized in NP40 lysis buffer (20 mM Tris-HCl 
pH 7.5, 150 mM NaCl, 2 mM EGTA, 1% Nonidet P-40, 10 mM β-glycero-
phosphate, 5 mM NaF, 1 mM NaPPi, 2 mM DTT, 1 mM sodium vanadate, 
100 µM PMSF) and cleared by centrifugation at 6,000 g (15 minutes; 4°C). 
Fifty micrograms of homogenates were subjected to Western blot analysis. 
Quantifications of Western blots were performed and expressed relative to 
actin levels. Human biopsy samples were procured in accordance with the 
guidelines as adopted and promulgated by the NIH. Permission to perform 
the experiments with the samples was granted by the Scientific Advisory 
Board of the Harvard Brain Tissue Resource Center at McLean Hospital 
(Belmont, Massachusetts, USA).
Cell culture, transfection, and immunofluorescence. Primary cultures of stria-
tal neurons were prepared from E17 Sprague-Dawley rats and transfected 
at 4 days in vitro by a modified calcium phosphate technique (24). Mouse 
neuronal cells derived from wild-type huntingtin mouse (neuronal cells, +/+) 
and from Hdh109Q/109Q knock-in mouse (109Q/109Q) were cultured as previ-
ously described (28) and transfected with Lipofectamine 2000 (Invitrogen 
Corp.). Human 293T cells were cultured in DMEM supplemented with 10% 
bovine calf serum. Transfected neuronal cells were grown on glass coverslips, 
fixed with 4% paraformaldehyde for 20 minutes, and immunostained as pre-
viously described (27). For experiments represented in Figures 4B and 5E, 
cells were fixed with methanol/acetone (vol/vol) at –20°C for 10 minutes.
Measurement of neuronal survival and intranuclear inclusions. Four days after 
plating, primary cultures of striatal neurons were transfected with wild-type 
or polyQ-huntingtin and GFP to identify the transfected cells. To be certain 
that each neuron synthesizing GFP also expressed the huntingtin construct, 
transfections were performed using a derived phosphate calcium method 
with a high ratio of huntingtin DNA to GFP DNA (10:1) (65). Under these 
conditions more than 95% of the GFP-positive neurons also expressed the 
huntingtin construct (data not shown). GFP-positive neurons were scored 
using fluorescence microscopy in a blinded manner 16 hours and 36 hours 
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after transfection. Cell death occurring within the GFP-positive cells was 
determined as the difference in the number of surviving neurons between 
the 2 time points and expressed as percentage of cell death. For intranuclear 
inclusions scoring, striatal neurons were transfected with vectors of inter-
est and a plasmid encoding β-galactosidase (10:1). Neurons were fixed 5 
days after transfection, immunostained, and analyzed for the presence of 
ubiquitin-positive intranuclear inclusions (anti–β-galactosidase, 1:300; 
5 Prime–3 Prime Inc.; anti-ubiquitin, 1:100; Dako). Each graph represents 
2–3 independent experiments performed in triplicate. Each bar in a given 
graph corresponds to the scoring of about 2,000 neurons in neuronal sur-
vival experiments and 500 neurons for inclusions scoring.
C. elegans assays. Nematode strains were handled following traditional 
methods (66). All strains were received from the Caenorhabditis Genetics 
Center, University of Minnesota. Construction of huntingtin transgenics, 
touch response assays, and visualization of neurons were carried out as 
described previously (32, 33). Transgenic strains expressing human HSJ1b 
were constructed by microinjection of lin-15(n765ts) animals with a mix 
of wild-type lin-15 (50 ng/µl), Pstr-1:GFP (15 ng/µl), and Pmec-7:HSJ1b (15 
ng/µl). Independent stable lines were established, and 4 lines with simi-
lar HSJ1b expression levels were chosen for further study. The 19Q-HSJ1b 
(n = 444) and 128Q-HSJ1b (n = 388) transgenics were obtained by crossing 
HSJ1b transgenics with lines expressing stably integrated Pmec-3:htt57Q19:
GFP or Pmec-3:htt57Q128:GFP. Animals expressing control (exon 1–19Q-
GFP) were 50.1% ± 2.4% touch sensitive at the tail, and animals expressing 
mutant transgene (exon 1–128Q-GFP) were 7% ± 1.1% touch sensitive. Data 
are from at least 3 independent experiments performed in triplicate.
Aggregation was observed in all strains expressing the exon 1–128Q-GFP 
transgene. Images of worm mechanosensory neurons were captured from at 
least 100 animals for each strain over 5 different trials. Aggregation was mea-
sured as average gray value using MetaView software (Molecular Devices). 
Data are from at least 3 independent experiments performed in triplicate.
Cell extracts, subcellular fractionation, preparation of CCVs, and Western blots. 
Cell extracts were obtained by lysing cells 48 hours after transfection with 
NP40 lysis buffer (2 minutes; 4°C). The extracts were sonicated and centri-
fuged at 11,000 g (15 minutes; 4°C). Proteins were loaded onto SDS-PAGE 
and subjected to Western blot analysis. For the experiment represented 
in Figure 2B, the samples were loaded without prior centrifugation. The 
aggregates remained in the stacking gel, whereas the soluble form migrated 
in the resolving gel. The aggregates were solubilized by formic acid treat-
ment of the NP40 extracts (total) (31).
Subcellular fractionation was performed 48 hours after transfection as 
described previously (27). T represents the total extract, and fractions P1, 
P2, S3, and P3 were obtained using differential centrifugations: P1, initial 
pellet of homogenate; P2, crude synaptosomes; P3 and S3, high-speed pel-
let and supernatant of P2, respectively.
CCVs were purified from transfected cells (67). Cells were homogenized 
in buffer A [0.1 M 2-(N-morpholino)ethane-sulfonic acid, pH 6.5; 1 mM 
EGTA; 0.5 mM MgCl2; 0.83 mM benzamidine; 0.23 mM phenylmethyl-
sulfonyl fluoride; 0.5 µg/ml aprotinin; and 0.5 µg/ml leupeptin]. The 
homogenate was centrifuged at 17,800 g for 20 minutes, and the super-
natant was collected and centrifuged at 56,100 g for 1 hour. The pellet 
was resuspended in buffer A, followed by dispersion through a 25-gauge 
needle. The resuspended pellet was loaded on top of a solution containing 
8% sucrose in buffer A and centrifuged for 2 hours at 115,800 g. The super-
natant (s) and the pellet containing the CCVs (p) were collected.
Antibodies. Antibodies used included: mouse monoclonal anti–β-actin 
AC15 (Sigma-Aldrich), anti-myc 9E10 (Calbiochem), anti–HA 16B12 
(Covance Research Products Inc.), anti-clathrin, and anti-GM130 (BD 
Biosciences — Pharmingen); sheep polyclonal anti-HSJ1 (sHSJ11-277) (29); 
rabbit polyclonal anti-BDNF (Santa Cruz Biotechnology Inc.), anti-GFP 
(Chemicon International), and anti–endoplasmic reticulum (68); human 
polyclonal anti–GMAP-210 (38).
Anti-mouse and anti-rabbit secondary antibodies conjugated to HRP 
were purchased from Jackson ImmunoResearch Laboratories Inc. Anti-
mouse and anti-rabbit secondary antibodies conjugated to Alexa Fluor 
(A488, A555, and A630) were from Invitrogen Corp. Pictures of fixed cells 
were captured with a 3D deconvolution imaging system.
Analysis of 3D images. The amount of clathrin-positive BDNF vesicles was 
quantified by measuring the colocalization between the 2 markers. Briefly, 
both clathrin and BDNF pictures were thresholded to segment vesicles 
and binarized. The percentage of colocalization was defined on binarized 
images as the ratio of clathrin-positive pixels overlapping BDNF-positive 
pixels to the total number of BDNF-positive pixels.
Quantification of Golgi area or vesicles that contained BDNF was 
achieved using the integrated morphometry analysis (IMA) from Meta-
Morph software version 6.2.6 (Molecular Devices). BDNF vesicles were 
defined by thresholding images to remove the background. Using an IMA 
size filter, objects ranging from 1–50 pixels (67 nm–3.35 µm diameter) were 
considered as vesicles and scored (cytoplasmic BDNF vesicles), whereas the 
bigger perinuclear structure was considered to be Golgi apparatus. The 
associated signal (pixel intensity) was recorded and corresponds to the 
quantity of BDNF in the defined structures (BDNF content in Golgi or 
BDNF content in cytoplasmic vesicles). Data are from at least 3 indepen-
dent experiments, with a minimum of 5 cells analyzed per condition.
BDNF immunoenzyme assays. BDNF assays were performed 48 hours after 
lipofection of neuronal cells. Cells were washed with PBS and incubated 30 
minutes with DMEM alone or DMEM containing 100 µM cystamine, and 
the supernatants were collected. For the time-course experiments, the incu-
bation times with DMEM with or without cystamine were as stated. For 
BFA experiments, cells were first depolarized twice as previously described 
(27) in the absence or presence of BFA (5 µM). Cells were then washed and 
treated for 30 minutes with DMEM or cystamine (100 µM). The amount of 
BDNF was measured in supernatants and cell lysates using the BDNF Emax 
ImmunoAssay system (Promega). The data from transfected or treated cells 
are from at least 3 independent experiments performed in triplicate.
Animals. All experimental procedures were performed in strict accordance 
with the recommendations of the European Community (86/609/EEC) and 
the French National Committee (87/848) for care and use of laboratory ani-
mals. Live animal experiments were approved by the French Ethical Com-
mittee established by the Ministère de l’Agriculture et de la Forêt, Direction 
des Services Vétérinaires-Protection et Santé Animale (Evry, France).
R6/1 (bdnf +/+httm) mice (46), BDNF heterozygous (bdnf+/–htt+/+) mice (69), 
and bdnf+/–httm double-mutant mice (26) were used in this study. All experi-
ments were performed on male littermates from the F2 population to avoid 
strain and sex differences. Mice were housed together in numerical birth 
order in groups of mixed genotypes, and data were recorded for analysis by 
microchip mouse number. All experiments were conducted in a blinded 
manner with respect to genotype. Thirty minutes after the last administra-
tion of cysteamine (cysteamine bitartrate, or Cystagon [Orphan Europe], 
per os), 26- to 28-week-old mice (n = 4–5 per condition) were deeply anes-
thetized in a CO2 chamber, and their striata were dissected out on ice and 
rapidly frozen using CO2 pellets. Samples were then homogenized in lysis 
buffer (137 mM NaCl, 20 mM Tris-HCl, pH 8.0, 1% Igepal, 10% glycerol, 
1 mM PMSF, 10 µg/ml aprotinin, 1 µg/ml leupeptin), sonicated, and cen-
trifuged (10 minutes, 6,000 g at 4°C). BDNF contents were determined in 
duplicate by the Emax ImmunoAssay system using 300 µg of total protein 
for each point. C57BL/6 mice (males, age 5–6 weeks) were purchased from 
Charles River Laboratories. The Hdh109Q mice (males, age 15 weeks) have 
been previously described (45). Treatments with cystamine (Sigma-Aldrich; 
intra-peritoneal injections) or cysteamine started on day 1 with 100 mg/kg 
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and were gradually increased to reach 300 mg/kg on day 7 (1 week). Mice 
were killed 30 minutes after the last administration. Blood was subjected 
to centrifugation (5 minutes; 2,700 g), and supernatant (serum) was kept. 
BDNF levels were determined using 600 µg of total protein (BDNF Emax 
ImmunoAssay system). A half frontal hemisphere of the brain was homog-
enized in NP40 lysis buffer and centrifuged 6,000 g (15 minutes; 4°C), 
and 100 µg of total protein of the supernatant was used to determine the 
amount of BDNF (BDNF Emax ImmunoAssay system).
Six-month-old male Sprague-Dawley rats (n = 4) weighing 550–580 g 
(Charles River Laboratories) were used for determination of the blood lev-
els of BDNF at different time points before and after injection of either 
cysteamine (cysteamine dihydrochloride [Sigma-Aldrich]; 100 mg/kg; 
intramuscular injection) or its vehicle (physiological saline solution). For 
blood sampling, animals were anesthetized by inhalation of a mixture of 
isoflurane (1%), nitrous oxide (66%), and oxygen (33%). A catheter was 
inserted into and secured in the femoral vein. Blood samples (∼300 µl) were 
collected every 15 minutes for 150 minutes.
Two long-tailed macaques (Macaca fascicularis) weighing 7.5 and 7 kg 
were treated for 14 months on a daily basis with slowly increasing doses 
of 3NP as previously described (49). At the time of blood collection, the 
3NP dose was 30 mg/kg/d given in 2 daily injections (1 injection at 9 am, 
1 injection at 5 pm). These 2 animals had no overt striatal degeneration 
as assessed by magnetic resonance (MR) imaging, but based on localized 
proton MR spectroscopy examination, they showed reduced tricarbox-
ylic acid cycle turnover and depletion in N-acetyl-aspartate, glutamate, 
and GABA in the striatum. For blood sampling, the monkeys received 
a mixture of ketamine (15 mg/kg; Ketalar; PANPHARMA) and xylazine 
(1.5 mg/kg; Rompun; Bayer) before intubation. Animals were then anes-
thetized using an isoflurane/nitrous oxide mixture (1:66), controlled by 
an Ohmeda ventilator (Ohmeda OAV 7710; Datex-Ohmeda) with 33% 
oxygen. The tidal volume was adjusted to achieve stable end-tidal CO2 
tension between 38 and 40 mmHg.
After insertion of Teflon catheter into the saphena vein, blood samples 
(500 µl) were collected every 15 minutes for 45 minutes before cysteamine 
injection. Cysteamine treatment (cysteamine hydrochloride [Sigma-Aldrich], 
100 mg/kg) was made by intramuscular injection in the hind limbs. Then 
blood samples were collected every 15 minutes for 120 minutes.
Immunohistochemistry. Cresyl violet staining and immunohistochemistry 
assays were performed on paraformaldehyde-fixed material as described 
previously (26). Administration of cysteamine or its vehicle was performed 
in 26-week-old mice (n = 4–5 per condition); 2 hours after the last admin-
istration, animals were deeply anesthetized and transcardially perfused 
with 4% paraformaldehyde solution in 0.1 M sodium phosphate, pH 7.2, 
at 15 days and 30 weeks of age. The brains were postfixed for 2 hours in 
the same solution, cryoprotected in increasing concentrations of sucrose/
PBS (10–30%), and frozen in dry ice–cooled isopentane. Serial sections of 
30 µm depth were obtained every 0.3 mm and were processed for cresyl 
violet staining and immunohistochemistry.
Sections were processed as free-floating for immunohistochemistry. To 
block endogenous peroxidases, sections were incubated for 30 minutes 
with PBS containing 10% methanol and 3% H2O2. Sections were washed 
3 times in PBS and blocked for 1 hour with 2–10% normal serum in PBS. 
Tissue was then incubated with the anti–DARPP-32 antibody (1:10,000; 
Chemicon International) in PBS containing 2% normal goat serum for 16 
hours at room temperature. Sections were washed 3 times and incubated 
with a biotinylated secondary antibody (1:200; Vector Laboratories) for 1–2 
hours at room temperature in the same buffer as the primary antibody. The 
immunohistochemical reaction was developed using the VECTASTAIN 
ABC kit (Vector Laboratories). No signal was detected in controls that cor-
responded to the same treatment without the primary antibody.
Cell counts were performed in a blind manner with respect to geno-
type. Unbiased stereological counts of striatal cells were obtained from 
the entire neostriatum using Computer Assisted Stereology Toolbox 
(CAST) software (Olympus). The dissector counting method was 
employed to analyze coronal sections spaced 300 µm apart. The count-
ing frames were randomly sampled. We counted the neuron-like cells 
in cresyl violet staining as the cells with a large nonpyknotic nucleus 
with clear nucleoli.
Quantification of DARPP-32–positive cells in the striatum of 3–4 ani-
mals per condition revealed significant differences (ANOVA, F5,15 = 8.98; 
P < 0.0004 [P < 0.05 was considered statistically significant]). There was 
a significant difference in the number of DARPP-32–positive cells per 
striatum between bdnf +/+httwt mice and bdnf +/+httm mice (post-hoc Fisher’s 
test, P = 0.003) and between bdnf +/+httwt mice and bdnf +/–httm mice with 
(post-hoc Fisher’s test, P = 0.00022) or without cysteamine treatment 
(post-hoc Fisher’s test, P = 0.00043). Cysteamine induced a significant 
increase in the number of DARPP-32–positive cells per striatum in 
bdnf +/+httm mice (post-hoc Fisher’s test, P = 0.048) but not in bdnf +/–httm 
mice (post-hoc Fisher’s test, NS).
In situ hybridization. Administration of cysteamine or its vehicle was 
performed in 17- to 18-week-old mice (n = 3–4). After 1 week, animals 
were killed 2 hours after the last administration, and brains were dis-
sected out and frozen in dry-ice cooled isopentane. Sections were pro-
cessed for in situ hybridization with radioactive oligonucleotide probes 
for preproenkephalin (PPE) as previously described (70). The slides were 
exposed to Biomax MR (Kodak) for 7 days. The expression of PPE was 
quantified on in situ hybridization films. Consecutive sections (18–20 
sections/animal) were scanned, and mRNA levels were analyzed using 
the ImageJ program (http://rsb.info.nih.gov/ij/). The striatal area was 
determined according to anatomical landmarks, and the intensity was 
quantified. The background signal of the same adjacent area outside of 
the brain was subtracted.
Quantification of ENK mRNA levels in 3–4 animals per each condi-
tion revealed significant differences (ANOVA, F7,16 = 17.71; P = 0.000002). 
There was a significant difference in ENK mRNA levels between bdnf+/+httwt 
mice and both bdnf +/+httm mice (post-hoc Fisher’s test, P = 0.0084) and 
bdnf +/–httm mice (post-hoc Fisher’s test, P = 0.000001); and between 
bdnf +/+httm mice and bdnf +/–httm mice (post-hoc Fisher’s test, P = 0.0024). 
Cysteamine treatment induced an increase in ENK mRNA levels in 
bdnf +/+httm mice (post-hoc Fisher’s test, P = 0.057) and in bdnf +/–httm mice 
(post-hoc Fisher’s test, P = 0.0002).
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